These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 36316466)

  • 1. Intravesical ICIs to reduce toxicity in NMIBC.
    Masone MC
    Nat Rev Urol; 2022 Dec; 19(12):694. PubMed ID: 36316466
    [No Abstract]   [Full Text] [Related]  

  • 2. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
    Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
    BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Intravesical gene therapy for patients with BCG-refractory NMIBC?].
    Böhle A
    Urologe A; 2021 Mar; 60(3):372-373. PubMed ID: 33537869
    [No Abstract]   [Full Text] [Related]  

  • 4. Preoperative abdominal fat distribution and systemic immune inflammation were associated with response to intravesical Bacillus Calmette-Guerin immunotherapy in patients with non-muscle invasive bladder cancer.
    Ke ZB; Chen H; Chen JY; Cai H; Lin YZ; Sun XL; Huang JB; Zheng QS; Wei Y; Xue XY; Xu N
    Clin Nutr; 2021 Dec; 40(12):5792-5801. PubMed ID: 34775222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Ⅱ. Clinical Evidence and Biological Mechanism of BCG Failure in Patients with Non-Muscle Invasive Bladder Cancer].
    Miyake M
    Gan To Kagaku Ryoho; 2022 Jan; 49(1):33-38. PubMed ID: 35046358
    [No Abstract]   [Full Text] [Related]  

  • 6. Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis.
    Houghton BB; Chalasani V; Hayne D; Grimison P; Brown CS; Patel MI; Davis ID; Stockler MR
    BJU Int; 2013 May; 111(6):977-83. PubMed ID: 23253618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A Randomized Controlled Study of Intravesical Instillation Therapy of Bacillus Calmette-Guérin vs. Epirubicinin Treating Non-muscular Invasive Bladder Cancer].
    Yang WX; Shao YX; Hu X; Xiong SC; Liu Y; Li X
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 Mar; 52(2):326-333. PubMed ID: 33829710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-inflammatory use may not negatively impact oncologic outcomes following intravesical BCG for high-grade non-muscle-invasive bladder cancer.
    Singla N; Haddad AQ; Passoni NM; Meissner M; Lotan Y
    World J Urol; 2017 Jan; 35(1):105-111. PubMed ID: 27194044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intravesical instillation for bladder tumors].
    Rivière A; Ploussard G; Desgranchamps F
    Rev Prat; 2014 Dec; 64(10):1388-9. PubMed ID: 25665319
    [No Abstract]   [Full Text] [Related]  

  • 10. Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer.
    Zazzara M; Nazaraj A; Scarcia M; Cardo G; Carando R; Ludovico GM
    Urol Int; 2023; 107(1):64-71. PubMed ID: 34933307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: Sequential Intravesical Gemcitabine and Docetaxel for Bacillus Calmette-Guérin-naïve High-risk Nonmuscle-invasive Bladder Cancer.
    Kavoussi M; Nasrallah AA; Williams SB
    Eur Urol; 2022 Dec; 82(6):659. PubMed ID: 36089530
    [No Abstract]   [Full Text] [Related]  

  • 12. Management of BCG "Failures".
    Palou Redorta J
    Eur Urol; 2006 May; 49(5):779-80. PubMed ID: 16616207
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer.
    Bree KK; Hensley PJ; Brooks NA; Matulay J; Li R; Nogueras Gonzalez GM; Navai N; Grossman HB; Matin SF; Dinney CPN; Kamat AM
    BJU Int; 2021 Nov; 128(5):568-574. PubMed ID: 33484074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of bacillus Calmette-Guerin refractory non-muscle invasive bladder cancer.
    Turker P; Turkeri L
    Arch Esp Urol; 2013 Nov; 66(9):833-40. PubMed ID: 24231293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The search of new biomarkers in the prediction of BCG response in patients with high-risk NMIBC.
    Martinez Rodriguez RH; Amon Sesmero JH
    World J Urol; 2021 Feb; 39(2):629-630. PubMed ID: 32248362
    [No Abstract]   [Full Text] [Related]  

  • 16. In-home Intravesical Therapy: The Future of Nonmuscle-invasive Bladder Cancer Care Delivery?
    Lyon TD; Boorjian SA; Tyson MD
    J Urol; 2023 Apr; 209(4):656-658. PubMed ID: 36637416
    [No Abstract]   [Full Text] [Related]  

  • 17. Intravesical BCG treatment causes a long-lasting reduction of recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer.
    Thiel T; Ryk C; Renström-Koskela L; Steineck G; Schumacher MC; Wiklund NP; de Verdier PJ
    World J Urol; 2019 Jan; 37(1):155-163. PubMed ID: 29905887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What is the optimal BCG dose in non-muscle-invasive bladder cancer?
    Witjes JA
    Eur Urol; 2007 Nov; 52(5):1300-2. PubMed ID: 17531374
    [No Abstract]   [Full Text] [Related]  

  • 19. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
    Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
    Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
    Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
    BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.